Corcept Therapeutics (CORT) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 0.77.
- Corcept Therapeutics' Equity Ratio fell 581.12% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 581.12%. This contributed to the annual value of 0.81 for FY2024, which is 83.03% down from last year.
- According to the latest figures from Q3 2025, Corcept Therapeutics' Equity Ratio is 0.77, which was down 581.12% from 0.79 recorded in Q2 2025.
- Corcept Therapeutics' 5-year Equity Ratio high stood at 0.92 for Q1 2021, and its period low was 0.77 during Q3 2025.
- In the last 5 years, Corcept Therapeutics' Equity Ratio had a median value of 0.84 in 2024 and averaged 0.85.
- Per our database at Business Quant, Corcept Therapeutics' Equity Ratio tumbled by 1244.57% in 2023 and then surged by 480.76% in 2024.
- Quarter analysis of 5 years shows Corcept Therapeutics' Equity Ratio stood at 0.89 in 2021, then decreased by 3.01% to 0.86 in 2022, then dropped by 5.22% to 0.82 in 2023, then fell by 0.83% to 0.81 in 2024, then dropped by 5.1% to 0.77 in 2025.
- Its Equity Ratio stands at 0.77 for Q3 2025, versus 0.79 for Q2 2025 and 0.81 for Q1 2025.